In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy ...

The opening months of 2026 painted a vivid picture of a life sciences sector in rapid motion, stretched between scientific ...

Roche's recent run of positive study results with giredestrant has come to an end with the failure of the persevERA trial in ...

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary ...

STEM has spent nearly two decades supporting pharma companies with strategic insights. As Adam Boucher explained, the emergence of generative AI has opened new possibilities for analysing field ...

An artificial intelligence-powered digital health worker has been unveiled by the World Health Organisation (WHO) as its latest tool for disseminating reliable health information to the public.

The UK government has laid out a plan to become the leading life sciences power in Europe by 2030, but the pharma industry has already warned that it will fail without reforms to medicine funding and ...

The FDA has said it will expand unannounced inspections of overseas manufacturing facilities supplying medicine and other medical products to the US. The aim is to make sure that foreign companies ...

Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class. The Nasdaq-listed company – which is planning to rebrand as BeOne ...

Prasad was first appointed head of the FDA's Center for Biologics Evaluation and Research (CBER) in May 2025 – after his ...